Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
Jaffer
Farouc A
FA
D002340:Carotid Artery Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009525:Niacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D014280:Triglycerides; D009525:Niacin